biological source
rabbit
Quality Level
recombinant
expressed in HEK 293 cells
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
4C17, recombinant monoclonal
description
recombinant, expressed in HEK 293 cells
product line
ZooMAb® learn more
form
lyophilized
mol wt
calculated mol wt 146.81 kDa
observed mol wt ~200 kDa
purified by
using Protein A
species reactivity
human
species reactivity (predicted by homology)
rat, mouse
packaging
antibody small pack of 25
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
technique(s)
immunocytochemistry: suitable
inhibition assay: suitable
western blot: suitable
isotype
IgG
epitope sequence
C-terminal cytoplasmic domain
Protein ID accession no.
UniProt accession no.
shipped in
ambient
storage temp.
2-8°C
Gene Information
human ... ERBB4(2066)
General description
Receptor tyrosine-protein kinase erbB-4 (UniProt: Q15303; also known as EC:2.7.10.1, Proto-oncogene-like protein c-ErbB-4, Tyrosine kinase-type cell surface receptor HER4, p180erbB4) is encoded by the ERBB4 (also known as HER4) gene (Gene ID: 2066) in human. ErbB4 is a tyrosine-protein kinase that serves as a receptor for neuregulins and EGF family members. It is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-25), which is subsequently cleaved off to produce the mature form that contains an extracellular domain (aa 26-651), a transmembrane domain (aa 652-675), and a cytoplasmic domain (aa 676-1308). Its protein kinase domain is localized in amino acids 718-985. ErbB4 can be proteolytically processed to generate an intracellular domain (4ICD) that can translocate to nucleus to promote import and activation of STAT5A. 4ICD also translocates to mitochondria where it promotes apoptosis. ErbB4 is highly expressed in brain, heart, kidney, skeletal muscle, spleen, testis, and breast tissue. It is required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. It is also required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Ligand binding to ErbB4 triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. It is constitutively phosphorylated at a basal level and ligand binding LEADS to increased phosphorylation. Phosphorylation at Tyr-1035 is important for its interaction with STAT1 and phosphorylation at Tyr-1056 is required for its interaction with PIK3R1. Its phosphorylation at Tyr-1242 is important for interaction with SHC adaptor protein 1 (SHC1). Phosphorylation of ErbB4 at Tyrosine 1284 plays a crucial role in modulating its signaling pathways, particularly in response to neuregulin ligands. This modification is essential for the activation of downstream signaling cascades, including the PI3K/Akt and MAPK pathways, which are pivotal for cellular processes such as proliferation, differentiation, and survival. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, Affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Williams, CC., et al. (2004). J. Cell Biol. 167(3); 469-478; Komuro, A., et al. (2003). J. Biol. Chem. 278(35); 33334-33341; Harari, D., et al. (1999). Oncogene. 18(17); 2681-2689).
Immunogen
Application
Evaluated by Western Blotting in lysate from A-431 cells treated with EGF.
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected ErbB4 phosphorylated at (Tyr1284) in lysate from A-431 cells treated with EGF (50 ng/ml for 10 min) but, not in lysate from untreated A-431 cells.
Tested Applications
Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected ErbB4 phosphorylated at (Tyr1284) in serum starved A431 cells treated with EGF (50ng/ml EGF for 10 min).
Peptide Inhibition Assay: Target band detection in lysate from A-431 cells treated with EGF (50 ng/ml for 10 min) was prevented by pre-blocking of a representative lot with the immunogen phosphopeptide but not the corresponding non-phosphopeptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Physical form
Preparation Note
Legal Information
Disclaimer
Not finding the right product?
Try our Product Selector Tool.
Regulatory Information
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
